Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | PHASE1 | COMPLETED | 49 | — | — | Mar 26, 2019 | May 4, 2023 | Apr 2, 2025 | 5 | United States, Belgium +2 |
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| SL-279252 | EXPERIMENTAL | Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated |
| Name | Type | Description |
|---|---|---|
| SL-279252 | DRUG | The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L). |
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply. 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject has a histologi...